530 related articles for article (PubMed ID: 18781983)
1. The endocannabinoid system and multiple sclerosis.
Baker D; Pryce G
Curr Pharm Des; 2008; 14(23):2326-36. PubMed ID: 18781983
[TBL] [Abstract][Full Text] [Related]
2. Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis.
Pryce G; Baker D
Handb Exp Pharmacol; 2015; 231():213-31. PubMed ID: 26408162
[TBL] [Abstract][Full Text] [Related]
3. The endocannabinoid system in amyotrophic lateral sclerosis.
Bilsland LG; Greensmith L
Curr Pharm Des; 2008; 14(23):2306-16. PubMed ID: 18781981
[TBL] [Abstract][Full Text] [Related]
4. Role of cannabinoids in multiple sclerosis.
Zajicek JP; Apostu VI
CNS Drugs; 2011 Mar; 25(3):187-201. PubMed ID: 21323391
[TBL] [Abstract][Full Text] [Related]
5. [News about therapeutic use of Cannabis and endocannabinoid system].
Duran M; Laporte JR; Capellà D
Med Clin (Barc); 2004 Mar; 122(10):390-8. PubMed ID: 15033046
[TBL] [Abstract][Full Text] [Related]
6. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of cannabinoids in CNS disease.
Croxford JL
CNS Drugs; 2003; 17(3):179-202. PubMed ID: 12617697
[TBL] [Abstract][Full Text] [Related]
8. Towards cannabis and cannabinoid treatment of multiple sclerosis.
Croxford JL; Miller SD
Drugs Today (Barc); 2004 Aug; 40(8):663-76. PubMed ID: 15510238
[TBL] [Abstract][Full Text] [Related]
9. The endocannabinoid system in Huntington's disease.
Pazos MR; Sagredo O; Fernández-Ruiz J
Curr Pharm Des; 2008; 14(23):2317-25. PubMed ID: 18781982
[TBL] [Abstract][Full Text] [Related]
10. Endocannabinoid System: A Multi-Facet Therapeutic Target.
Kaur R; Ambwani SR; Singh S
Curr Clin Pharmacol; 2016; 11(2):110-7. PubMed ID: 27086601
[TBL] [Abstract][Full Text] [Related]
11. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide.
Loría F; Petrosino S; Mestre L; Spagnolo A; Correa F; Hernangómez M; Guaza C; Di Marzo V; Docagne F
Eur J Neurosci; 2008 Aug; 28(4):633-41. PubMed ID: 18657182
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis.
Khan H; Ghori FK; Ghani U; Javed A; Zahid S
Mol Biol Rep; 2022 Jun; 49(6):5117-5131. PubMed ID: 35182322
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoids and multiple sclerosis.
Pertwee RG
Pharmacol Ther; 2002 Aug; 95(2):165-74. PubMed ID: 12182963
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoids and the expanded endocannabinoid system in neurological disorders.
Cristino L; Bisogno T; Di Marzo V
Nat Rev Neurol; 2020 Jan; 16(1):9-29. PubMed ID: 31831863
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoids in depressive disorders.
Poleszak E; Wośko S; Sławińska K; Szopa A; Wróbel A; Serefko A
Life Sci; 2018 Nov; 213():18-24. PubMed ID: 30290188
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.
de Lago E; Moreno-Martet M; Cabranes A; Ramos JA; Fernández-Ruiz J
Neuropharmacology; 2012 Jun; 62(7):2299-308. PubMed ID: 22342378
[TBL] [Abstract][Full Text] [Related]
17. From cannabis to endocannabinoids in multiple sclerosis: a paradigm of central nervous system autoimmune diseases.
Malfitano AM; Matarese G; Bifulco M
Curr Drug Targets CNS Neurol Disord; 2005 Dec; 4(6):667-75. PubMed ID: 16375684
[TBL] [Abstract][Full Text] [Related]
18. The endocannabinoid-CB receptor system: Importance for development and in pediatric disease.
Fride E
Neuro Endocrinol Lett; 2004; 25(1-2):24-30. PubMed ID: 15159678
[TBL] [Abstract][Full Text] [Related]
19. Role of cannabinoids in chronic liver diseases.
Parfieniuk A; Flisiak R
World J Gastroenterol; 2008 Oct; 14(40):6109-14. PubMed ID: 18985799
[TBL] [Abstract][Full Text] [Related]
20. Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis.
Centonze D; Mori F; Koch G; Buttari F; Codecà C; Rossi S; Cencioni MT; Bari M; Fiore S; Bernardi G; Battistini L; Maccarrone M
Neurol Sci; 2009 Dec; 30(6):531-4. PubMed ID: 19768368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
